USTR Seeks Comments for Consideration or Reconsideration of SEC 301 Tariff Exclusions for Medical Products

Posted on Mar 24


The Office of the U.S. Trade Representative has invited public comments through at least June 25 to identify additional products potentially helpful to the U.S. Response to the COVID-19 virus. According to the notice, “throughout the process of administering its Section 301 action to combat China’s acts, policies and practices related to technology transfer, intellectual property, and innovation, the United States has prioritized health considerations, and it is taking additional action for that objective today. Today, in an effort to keep current on developments in our national fight against the coronavirus pandemic, USTR has opened a docket for members of the public, businesses, and government agencies to submit comments if they believe further modifications to the 301 tariffs may be necessary. This comment process does not replace the current exclusion process and supplements that process. Submissions are limited to comments on products subject to the tariff actions and relevant to the medical response to the coronavirus.”

The notice contains a link for those wishing to provide comments, and a full copy of the USTR notice can be found here.

Please contact your V. Alexander account team with any questions and follow us on our website for updates on this and other topics.